VolitionRx Limited (NYSE:VNRX) Q4 2024 Earnings Conference Call March 31, 2025 4:30 PM ET
Company Participants
Louise Batchelor – Chief Marketing & Communications Officer
Cameron Reynolds – President & Chief Executive Officer
Terig Hughes – Chief Financial Officer
Andrew Retter – Chief Medical Officer
Conference Call Participants
Bruce Jackson – The Benchmark Company
Ilya Zubkov – Freedom Broker
Steven Ralston – Zacks Investment Research
Operator
Good afternoon ladies and gentlemen and thank you for standing by. Welcome to VolitionRx Limited Fourth Quarter and Full Fiscal Year 2024 Earnings Conference Call. During today’s presentation, all parties will be in a listen-only mode. Following the presentation, the conference call will be opened for questions. [Operator Instructions] This conference call is being recorded today, March 31, 2025.
I would now like to turn the conference over to Louise Batchelor, Group Chief Marketing and Communications Officer. Please go ahead.
Louise Batchelor
Thank you and welcome, everyone, to today’s earnings conference call for VolitionRx Limited. Before we begin, I’d like to remind everyone that some of the information discussed on this conference call will include forward-looking statements covered under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on our beliefs as well as assumptions we have used based upon information currently available to us. Because these statements reflect our current views concerning future events, these statements involve risks, uncertainties and assumptions. Actual future results may vary significantly based on a number of factors that may cause the actual results or events to be materially different from future results, performance, or achievements expressed or implied by these statements.
We have identified various risk factors associated with our operations in our most recent annual report on Form 10-K. quarterly reports on Form 10-Q and other filings with the Securities